


## NAAD sodium

Cat. No.:	HY-117029
CAS No.:	104809-30-5
Molecular Formula:	C <sub>21</sub> H <sub>25</sub> N <sub>6</sub> NaO <sub>15</sub> P <sub>2</sub>
Molecular Weight:	686.39
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	-20°C, sealed storage, away from moisture
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



## SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 100 mg/mL (145.69 mM; Need ultrasonic)				
	DMSO : 10 mg/mL (14.57 mM; ultrasonic and warming and heat to 60°C)				
	Preparing Stock Solutions	Mass	1 mg	5 mg	10 mg
		Solvent			
		Concentration			
		1 mM	1.4569 mL	7.2845 mL	14.5690 mL
In Vivo	Preparing Stock Solutions	5 mM	0.2914 mL	1.4569 mL	2.9138 mL
		10 mM	0.1457 mL	0.7284 mL	1.4569 mL
	Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline				
	Solubility: ≥ 1 mg/mL (1.46 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)				
	Solubility: ≥ 1 mg/mL (1.46 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
In Vivo	Solubility: ≥ 1 mg/mL (1.46 mM); Clear solution				

## BIOLOGICAL ACTIVITY

Description	NAAD sodium (Deamido nad sodium), a functional NAD <sup>+</sup> precursor, is the substrate of glutamine-dependent NAD <sup>+</sup> synthetase. NAAD sodium is used to study the structure of nicotinate mononucleotide adenyltransferases <sup>[1][2]</sup> .
In Vitro	In peripheral blood mononuclear cells (PBMC), NAAD sodium is only expected to be produced in biosynthesis of NAD <sup>+</sup> from tryptophan and NA2, was elevated from less than 20 nM to as high as 0.91 μM <sup>[1]</sup> . Nicotinamide adenine dinucleotide synthetases (NADS) catalyze the amidation of nicotinic acid adenine dinucleotide (NAAD) to yield the enzyme cofactor nicotinamide adenine dinucleotide (NAD) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

### In Vivo

In mice, when nicotinic acid (NA) is provided by oral gavage, liver NA peaked (340 pmol/mg) in 15 min. Hepatic NA appearance is followed by an expected peak of 220 NAAD sodium at 1 h post gavage and a rise in hepatic NAD<sup>+</sup> from 990 baseline to 2200 at 2 h<sup>[1]</sup>.

NAAD sodium is reported in mouse liver when 500 mg/kg of radioactive nicotinamide (Nam) is injected intraperitoneally (IP) into the body cavity of mice. However, NAAD sodium is observed in kidneys, ovaries, lung, heart and brain in addition to liver in mice IP-injected with 500 mg/kg of NA but not Nam<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Samuel A J Trammell, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948.

[2]. J Biol Chem. 2005 Apr 15;280(15):15131-40. Ralf Jauch, et al. Structures of Escherichia coli NAD synthetase with substrates and products reveal mechanistic rearrangements.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA